CFO
CCCC icon

Callan Family Office’s C4 Therapeutics CCCC Stock Holding History

Callan Family Office’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.4K Hold
19,146
– – ﹤0.01% 1182
2026
Q1 		$50.4K Sell
19,146
-12,597
-40% -$29.7K ﹤0.01% 1110
2025
Q4 		$60.6K Buy
+31,743
New +$75.2K ﹤0.01% 1088

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Callan Family Office's CCCC Position: Q2 2026 in Review

Callan Family Office held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 19,146 shares worth $89.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1182.

Callan Family Office first reported a position in CCCC in Q4 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Callan Family Office held 19,146 shares of C4 Therapeutics worth $89.4K as of Q2 2026.
  • Callan Family Office left its C4 Therapeutics share count unchanged in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Callan Family Office's portfolio in Q2 2026, its #1182 holding.
  • Callan Family Office first reported a position in C4 Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.